Precision Financing challenges for solid tumor adoptive T-cell therapies

Eric NormanFoCUS, Research Briefs


Durable gene and cell therapies represent a unique challenge to the US healthcare insurer/payer landscape, given the one-time treatment and associated high upfront cost but potentially durable outcomes. Previous research briefs1,2 and a white paper3 have addressed financing and other challenges relating specifically to chimeric antigen receptor T (CAR-T) cell therapies.

Download FoCUS Research Brief 2019F212v048

Share the research